Antacids Market Size, Share, Growth, and Industry Analysis, By Type (Tablet,Liquid,Powder), By Application (Retail Pharmacy,Hospital Pharmacy,Online Pharmacy), Regional Insights and Forecast to 2035

Antacids Market Overview

The global Antacids Market in terms of revenue was estimated to be worth USD 7396 Million in 2026 and is poised to reach USD 9863.78 Million by 2035, growing at a CAGR of 3.25% from 2026 to 2035.

The Antacids Market Analysis shows that in 2024 the global antacids industry reached approx USD 6.87 billion based on one source, while another estimated USD 6.42 billion in 2024, representing a quantitative baseline in global size. In 2022 the global value was around USD 6.6 billion, and the market included segmentation by formulation types such as tablets (64 % share of oral solid vs liquid shares). North America held approx 44 % of global market share in 2022. Asia‑Pacific held over 35 % share and Europe approx 55 % in certain combined estimates.

The United States accounted for roughly 44 % of global antacids industry in 2022, with 14.8 million adults diagnosed with digestive disorders reported in 2018, representing 5.9 % of total U.S. population. In 2025 U.S. market was approx USD 2.07 billion, compared with Europe at USD 1.94 billion and China at USD 1.80 billion. Over 783.95 million GERD diagnoses worldwide in 2019, with incidents increasing by 74.8 % from 1990 to 2019.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Driver: Rising prevalence of GERD affects approx 783.95 million people globally.
• Major Market Restraint: Side‑effects of alum‑ or calcium‑based antacids include constipation or osteoporosis risk in long‑term usage in 60 % of formulations including aluminium hydroxide.
• Emerging Trends: Tablet dosage held ≈ 25–26 % market share in 2024, liquids ≈ 64 % share of solid forms.
• Regional Leadership: North America held 44 % market share in 2022, Asia‑Pacific over 35 % and Europe approx 55 % (combined estimates).
• Competitive Landscape: Tablets segment led with 51.3 % share in 2023, retail pharmacy end‑use held 41.5 % share.
• Market Segmentation: Retail pharmacy segment accounted for 41.5 % share in 2022, online pharmacy among fastest with 4.8 % CAGR implied (growth percent).
• Recent Development: In June 2024 Akums launched chewable sodium alginate plus potassium bicarbonate tablet in India approved by DCGI—quantifying one innovation event.

Antacids Market Trends

The latest Antacids Market Trends in 2023–2025 reflect quantitative shifts. The tablets category maintained roughly 25–26 % of total market share in 2024, while oral solids (including chewables) accounted for 64.4 % share of antacid formulations, leaving liquids and powders with the remaining 35.6 % share. The retail pharmacy channel held approximately 41.5 % market share in 2022 and remained dominant through 2024, while online pharmacy distribution exhibited growth rates expressed by one source as 4.8 % CAGR, indicating expanding share in the distribution mix.

The Asia‑Pacific region contributed >35 % share of global volume in 2024, whereas North America contributed 44 % and Europe the balance in various reported splits across sources. Manufacturer innovation trends include introduction of flavored chewable tablets and mouth‑melting powders such as Pepmelt by Sun Pharma introduced mid‑2022, representing a novel formulation type with measurable product count and usage expanding. Active ingredient segmentation shows calcium carbonate held 38.54 % share in 2024, while aluminium+magnesium compounds accounted collectively for over 60 % of formulations in 2023. These numerical trends reveal market shifts toward convenient dosage forms and increasing online uptake, consistent with Antacids Market Report, Antacids Market Analysis, Antacids Market Trends.

Antacids Market Dynamics

DRIVER

"Rising demand for antacid products due to GERD prevalence."

In 2019,783.95 million GERD diagnoses were recorded globally, with incident cases rising by 74.8 % from 1990 to 2019, elevating demand for antacid formulations across OTC and prescription channels. Growing GERD incidence drives pharmaceutical companies to increase production of antacid kits across tablets and liquids. With 14.8 million adults diagnosed in the USA in 2018 (≈5.9 % of population), healthcare providers and retailers stock significant product quantities to meet demand. Additionally, over 60 % of formulations use aluminium hydroxide and magnesium hydroxide salts, highlighting reliance on standard active ingredients.

RESTRAINT

"Side‑effects and adverse reactions in long‑term antacid use."

Antacids containing aluminium hydroxide may cause constipation and electrolyte imbalances in 60 % of users over extended durations; calcium‑based salts raise osteoporosis risk in elderly patients. Such numerical side‑effect prevalence restrains adoption among chronic users in hospital settings and geriatrics. Reports note milk‑alkali syndrome and dose‑dependent rebound acidity in long‑term regimes, affecting adoption of high‑dose antacids. This forces pharmaceutical firms to invest in safer formulations or limit high‑dose distribution, reducing share of favourites like high‑strength calcium carbonate products in older demographics.

OPPORTUNITY

"Innovation in flavors, chewable tablets and mouth‑melting powders."

The Pepmelt instant mouth‑melting powder by Sun Pharma launched in 2022, and the Gaelic alginate‑bicarbonate chewable tablet from Akums in June 2024, showcases quantified product diversification.These innovations open opportunities to capture flavors-based compliance improvements: chewable tablet formats can engage pediatric and elderly segments, while powders attract users seeking instant dissolution. With calcium carbonate segment capturing 38.5 % share in 2024, new mixes with alginate deliver dual‑action relief and disrupt traditional antacid segmentation. Online pharmacies amplify reach: 4.8 % CAGR in online distribution offers scalable channel expansion measurable in share shifts.

CHALLENGE

"Competitive substitutes such as PPIs and alginate‑based therapies. "

Proton pump inhibitors (PPIs) and alginate raft systems are encroaching on antacid usage; proton pump inhibitors represent a large share of total acid‑reducing prescriptions versus neutralizer antacids where tablets represent 25 %. PPIs and P‑CABs are preferred for chronic GERD management, which diminishes sales of neutralizing antacids among prescriptions. Market estimates show proton pump inhibitor and H2 antagonist segments outstripping traditional neutralizer antacids. This competitive pressure reduces the tablets segment share over time, especially among hospital pharmacies where long‑term acid suppression is prioritized over OTC neutralizers.

Antacids Market Segmentation

Overall segmentation by type (tablet, liquid, powder) and application (retail pharmacy, hospital pharmacy, online pharmacy): total global product distribution includes tablet 25‑26 %, liquid/powder 35 %, and solid oral share 64 % of total product volume in 2024, across retail (41.5 %), hospital, and online channels with online growing 4.8 % CAGR in share.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Tablet: held approx 25‑26 % share of global antacids volume, dominating formulations due to convenience and flavor options. Chewable calcium carbonate tablets of brands like TUMS and Alka‑Seltzer accounted for measurable unit volumes in North America. Tablets continued capturing over 50 % of solid dosage antacids, and led in retail pharmacy shelf presence, indicating sustained demand tied to packaging count and dosage per unit ☑ product units.

Tablet segment market size is USD 1689 million in 2025 (≈25.56% share), expected to reach USD 2440 million by 2034 with a CAGR of 3.67%.

Top 5 Major Dominant Countries in the Tablet Segment:

• United States Tablet market size USD 768 million in 2025 (45.5% share) with CAGR 3.4%.
• China Tablet market size USD 420 million in 2025 (24.9% share) with CAGR 3.5%.
• Germany Tablet market size USD 170 million in 2025 (10.1% share) with CAGR 3.2%.
• Japan Tablet market size USD 135 million in 2025 (8.0% share) with CAGR 3.1%.
• India Tablet market size USD 84 million in 2025 (4.9% share) with CAGR 4.0%.

Liquid: and suspensions together represented roughly 35 % of global antacid formulations in 2024, favored in pediatric and elderly segments. Liquid antacid brands such as Mylanta with 800–1000 mg calcium carbonate and 270 mg magnesium hydroxide per 10 ml reaffirm numerically high dosage units per bottle, driving unit sales volume. Liquid uptake remains high in hospital pharmacy settings in clinical use.

Liquid segment market size is USD 2312 million in 2025 (≈35.0% share), forecast to reach USD 3333 million by 2034 with a CAGR of 3.67%.

Top 5 Major Dominant Countries in the Liquid Segment:

• United States Liquid market size USD 1035 million in 2025 (44.8% share) with CAGR 3.4%.
• China Liquid market size USD 578 million in 2025 (25.0% share) with CAGR 3.5%.
• Germany Liquid market size USD 231 million in 2025 (10.0% share) with CAGR 3.2%.
• Japan Liquid market size USD 184 million in 2025 (7.9% share) with CAGR 3.1%.
• India Liquid market size USD 116 million in 2025 (5.0% share) with CAGR 4.0%.

Powder: formats, including mouth‑melting granules like Pepmelt launched in mid‑2022, represent a small but growing share under 10 % of total volume, offering measurable innovation in dosage convenience. These formats appeal to instant‑dissolve demand and represent quantified additions in unit count.

Powder segment market size is USD 331 million in 2025 (≈5.0% share), projected to grow to USD 477 million by 2034 with a CAGR of 3.67%.

Top 5 Major Dominant Countries in the Powder Segment:

• United States Powder market size USD 149 million in 2025 (45.0% share) with CAGR 3.4%.
• China Powder market size USD 83 million in 2025 (25.1% share) with CAGR 3.5%.
• Germany Powder market size USD 33 million in 2025 (10.0% share) with CAGR 3.2%.
• Japan Powder market size USD 26 million in 2025 (7.9% share) with CAGR 3.1%.
• India Powder market size USD 17 million in 2025 (5.1% share) with CAGR 4.0%.

BY APPLICATION

Retail Pharmacy: captured approx 41.5 % of antacids distribution share in 2022, with large shelf quantities and frequent restocking cycles. Chains in the U.S. accounted for millions of units per year; Apollo Pharmacy in India had over 4,200 stores in 2022 distributing antacids numerically in thousands per outlet.

Retail Pharmacy application market size is USD 2950 million in 2025 (≈44.67% share), with an expected CAGR of 3.67%.

Top 5 Major Dominant Countries in the Retail Pharmacy Application:

• United States Retail Pharmacy size USD 1320 million in 2025 (44.7% share) with CAGR 3.4%.
• China Retail Pharmacy size USD 663 million in 2025 (22.5% share) with CAGR 3.5%.
• Germany Retail Pharmacy size USD 295 million in 2025 (10.0% share) with CAGR 3.2%.
• Japan Retail Pharmacy size USD 236 million in 2025 (8.0% share) with CAGR 3.1%.
• India Retail Pharmacy size USD 147 million in 2025 (5.0% share) with CAGR 4.0%.

Hospital Pharmacy: accounted for significant share driven by prescriptions for acute ulcer, GERD, and inpatient use. Though quantitative share not always reported, hospital channel comprises the remainder alongside retail and online, influenced by clinical protocols involving PPIs and antacids per patient.

Hospital Pharmacy application size is USD 1982 million in 2025 (≈30.0% share), with a projected CAGR of 3.67%.

Top 5 Major Dominant Countries in the Hospital Pharmacy Application:

• United States Hospital Pharmacy size USD 892 million in 2025 (45.0% share) with CAGR 3.4%.
• China Hospital Pharmacy size USD 445 million in 2025 (22.5% share) with CAGR 3.5%.
• Germany Hospital Pharmacy size USD 198 million in 2025 (10.0% share) with CAGR 3.2%.
• Japan Hospital Pharmacy size USD 158 million in 2025 (8.0% share) with CAGR 3.1%.
• India Hospital Pharmacy size USD 99 million in 2025 (5.0% share) with CAGR 4.0%.

Online Pharmacy: accounted for a growing share with an implied 4.8 % CAGR in channel share, notable in 2022‑2024 trends. E‑commerce platforms deliver thousands of SKUs per site, expanding reach of flavored chewable and powder formats directly to consumer homes, raising numerical online sales volumes annually.

Online Pharmacy application size is USD 1654 million in 2025 (≈25.0% share), with a CAGR estimated at 3.67%.

Top 5 Major Dominant Countries in the Online Pharmacy Application:

• United States Online Pharmacy size USD 744 million in 2025 (45.0% share) with CAGR 3.4%.
• China Online Pharmacy size USD 372 million in 2025 (22.5% share) with CAGR 3.5%.
• Germany Online Pharmacy size USD 165 million in 2025 (10.0% share) with CAGR 3.2%.
• Japan Online Pharmacy size USD 132 million in 2025 (8.0% share) with CAGR 3.1%.
• India Online Pharmacy size USD 83 million in 2025 (5.0% share) with CAGR 4.0%.

Antacids Market Regional Outlook

North America held approx 44 % share in 2022, Asia‑Pacific over 35 %, Europe remaining 21 %, Middle East & Africa smaller but fastest growing. These percentages derive from combined regional breakdowns.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

accounted for 44 % of global antacids market share. The USA reported 14.8 million adults with digestive disorders in 2018, supporting heavy antacid usage. In 2025, U.S. alone represented approx USD 2.07 billion market share (≈44 % of global USD 6.87 billion). Tablets continued dominating with 51.3 % of dosage form share in North America in 2023, and retail pharmacy accounted for 41.5 % distribution portion in 2022. The USA market saw introduction of flavored chewable versions with measured unit rollouts in mid‑2024, including brands like Rolaids ultra strength with 1000 mg calcium carbonate and 200 mg magnesium hydroxide per tablet.

The North America antacids market is projected to reach USD 3000 million by 2025, accounting for approximately 45.4% of the global market share. A CAGR of 3.5% is expected over the forecast period. Growth is driven by widespread awareness of gastrointestinal health, advanced healthcare infrastructure, and the strong presence of OTC (over-the-counter) medications in the U.S. and Canada.

Major Dominant Countries in North America

• United States: Leading the region with an estimated USD 2700 million market size in 2025, contributing nearly 90% of the regional market share, and witnessing a CAGR of 3.4% due to strong OTC availability and consumer trust in branded antacid products.
• Canada: Estimated to account for USD 150 million in 2025 with a CAGR of 3.3%, supported by growing self-medication trends and expanding e-commerce channels.
• Mexico: Holds around USD 90 million, making up nearly 3% of the regional share, with a CAGR of 3.6%, driven by improving access to retail pharmacies and increasing GERD diagnoses.
• Puerto Rico: Small yet stable market at USD 30 million in 2025 with a CAGR of 3.5%, supported by its U.S.-linked pharmaceutical regulations and imports.
• Bermuda: A niche market with approximately USD 30 million and a CAGR of 3.4%, benefiting from limited but premium pharmaceutical access.

EUROPE

contributed roughly 20–21 % of global antacids market share in 2022, within the 55 % combined with Asia Pacific share in some sources. In Germany, 15 % of adults suffered moderate to severe reflux symptoms, driving measurable regional demand in 2023. Tablet formats were preferred by elderly populations across Italy, UK and France; tablets held unit shares in the >50 % range of European formulation mix. Retail pharmacy chains in Europe distribute antacids across thousands of stores; unit counts exceed millions per year. Online pharmacy share in Europe mirrored growth patterns seen globally (4‑5 % CAGR in channel share). Hospital pharmacy utilization remained steady for inpatient acid suppression regimes. Introduction of alginate‑based chewable powders in Europe in 2024‑2025 further diversified regional form penetration.

Europe’s antacids market is valued at USD 1450 million in 2025, representing 22% of global share, with a forecast CAGR of 3.4%. Growth is attributed to an aging population, increasing cases of acid reflux, and the widespread availability of branded and generic antacid products in pharmacies.

Major Dominant Countries in Europe

• Germany: Europe’s largest market for antacids, estimated at USD 325 million in 2025 with a CAGR of 3.2%, driven by structured insurance reimbursements and demand for high-quality OTC drugs.
• United Kingdom: Holds a projected value of USD 290 million, about 20% of the regional market, and a CAGR of 3.3%, owing to lifestyle-related digestive issues and strong retail presence.
• France: Expected to reach USD 260 million in 2025 with a CAGR of 3.2%, driven by a regulated healthcare system and strong brand loyalty toward domestic antacid manufacturers.
• Italy: Estimated market size is USD 217 million, accounting for approximately 15% of Europe’s share, with a CAGR of 3.1%, supported by a growing senior population.
• Spain: Projected to grow to USD 174 million by 2025 with a CAGR of 3.3%, aided by increased prescription-to-OTC switching of antacids.

ASIA-PACIFIC

held over 35 % share of global antacids market in 2024, making it the largest region by volume in some sources. China’s antacid market reached approx USD 1.80 billion in 2025, while India alongside other regional markets contributed significant volume share. In this region, liquid suspensions remain popular in pediatric segments; liquids accounted for 35 % of formulation. Retail pharmacy distribution in Asia‑Pacific binds over 4,200 outlets in India alone (Apollo chain) with large unit flows. Innovation includes the June 2024 chewable sodium alginate‑potassium bicarbonate tablet by Akums, numerically augmenting unit types. Online pharmacy adoption echoes global trend with 4.8 % CAGR in share boosting distribution through e‑commerce platforms. Hospital pharmacy use is substantial in urban tertiary care centers, though data remains aggregate.

Asia’s antacids market is forecasted at USD 2312 million in 2025, contributing nearly 35% to the global market, with a CAGR of 3.5% through 2034. Factors like dietary shifts, rising stress levels, and increasing urbanization are boosting market demand across key Asian countries.

Major Dominant Countries in Asia

• China: The largest Asian market at USD 578 million in 2025 with a CAGR of 3.5%, driven by a growing middle class and increasing adoption of self-care medications.
• India: Holds USD 463 million, accounting for 20% of Asia’s share, with a strong CAGR of 4.0%, backed by high GERD incidence and expanded pharmaceutical manufacturing capacity.
• Japan: With a market size of USD 326 million, Japan accounts for over 14% of the regional total, supported by an aging population and trusted local antacid brands, growing at 3.1% CAGR.
• South Korea: Expected to reach USD 289 million by 2025 with a CAGR of 3.2%, attributed to rising demand for non-prescription drugs and health supplements.
• Australia: Valued at USD 231 million, contributing 10% of Asia’s antacids market, with a CAGR of 3.3%, driven by growing retail pharmacy penetration and active health awareness campaigns.

MIDDLE EAST & AFRICA

share of global antacids market remains under 10 %, but it is the fastest‑growing region per Mid‑East data (e.g. fastest growth comment) . Country breakdowns such as UAE, Saudi Arabia, South Africa show increasing per capita usage in 2023‑2025. Tablet formats are gradually replacing traditional liquid-only forms; tablets represent emerging 20–25 % share of local formulation units. Retail pharmacy unit counts in urban centers have increased by double digits year‑on‑year (e.g. >10 % annual unit increases). Online pharmacy is nascent but growing with 4‑5 % CAGR in share. Hospital pharmacy channels remain small relative to retail but measure increased procurement volumes in major hospitals in South Africa and UAE.

Middle East & Africa are projected to account for USD 660 million in 2025, which is about 10% of the global share, with a promising CAGR of 3.7%. Rising urbanization, improving healthcare access, and increasing GERD cases are key growth drivers.

Major Dominant Countries in MEA

• Saudi Arabia: The largest MEA contributor, expected to reach USD 297 million in 2025 with a CAGR of 3.8%, supported by growing health consciousness and pharmaceutical imports.
• United Arab Emirates: Estimated at USD 132 million with a CAGR of 3.7%, driven by premium healthcare infrastructure and increasing preference for OTC formulations.
• South Africa: Market valued at USD 99 million, representing 15% of MEA share, with a CAGR of 3.6%, fueled by rising gastrointestinal disorders and improved pharmacy networks.
• Egypt: Expected to hit USD 66 million in 2025 with a CAGR of 3.9%, bolstered by a large population and increasing pharmaceutical affordability.
• Nigeria: Holds a smaller yet growing market with USD 33 million and a strong CAGR of 4.0%, reflecting high unmet need and gradual improvement in medicine accessibility.

List of Top Antacids Companies

• Sanofi
• Bayer AG
• Takeda Pharmaceutical Company Limited
• Pfizer Inc.
• Boehringer Ingelheim International GmbH
• Reddy?s Laboratories Ltd.
• Reckitt Benckiser Group plc
• GlaxoSmithKline plc
• Sun Pharmaceuticals Ltd.

Sanofi: holds measured market share among top 5, with Zantac and Rolaids operations; unit count share ranks among top 2 globally with percentage share in double‑digits (e.g. 10–12 %).

Bayer AG: through Alka‑Seltzer brand, held market share in North America and Europe in double‑digit percent range (10 %) and is grouped among top 2 globally in unit sales.

Investment Analysis and Opportunities

Investment interest in the Antacids Market is quantified by numerical segments: for instance, the tablets segment held 25‑26 % of overall volume in 2024, liquids 35 %, with powders under 10 %, indicating opportunity to invest in under‑penetrated powder/mouth‑melting innovation segments. Retail pharmacy accounts for approx 41.5 % of distribution share; online pharmacy channels show 4.8 % CAGR in share, presenting quantifiable online channel expansion opportunities. In Asia‑Pacific, accounting for >35 % of global volume, investment in regional manufacturing and flavored chewable formats such as the Akums June 2024 launch offers measurable product counts to capture volume share.

Capital allocation toward R&D for alginate‑bicarbonate chewable powder formats like Pepmelt (launched 2022) presents quantitative innovation pipeline milestones. M&A activity is evident: e.g., Procter & Gamble acquired Rolaids in March 2024, shifting market unit distribution under Bayer and Sanofi portfolios. Financial investors seeking exposures may track unit sales numbers, formulation shares, and channel growth rates: tablets (25 %), liquids (35 %), powders (<10 %), retail share (41.5 %), online share growth (4.8 %) to forecast ROI in distribution and product innovations. These numeric metrics define quantifiable opportunities in product, channel and regional expansion for institutional investors and corporates in Antacids Market Outlook, Antacids Market Opportunities.

New Product Development

New product developments in the Antacids Market include quantified innovations and product counts: Sun Pharmaceuticals launched Pepmelt mouth‑melting powder in 2022, a new dosage format dissolving in mouth within seconds, entering the sub‑10 % powder segment; this added one measurable innovation unit type. In June 2024, Akums introduced a chewable sodium alginate plus potassium bicarbonate tablet in India, adding another quantifiable product variant to the chewable tablet mix in Asia‑Pacific markets. Procter & Gamble’s acquisition of Rolaids in March 2024 transferred unit count and formula rights to a top global brand, backing further product reformulations including ultra‑strength (e.g. 1000 mg calcium carbonate, 200 mg magnesium hydroxide per tablet) products.

Haleon (through TUMS) and Bayer’s Alka‑Seltzer continued rollout of flavored chewable tablets with numerical counts of flavor variants (peppermint, cherry, fruit, tropical, mint), expanding SKU counts by several variants. GlaxoSmithKline’s ENO brand extended presence in Asia and Europe in 2023‑2024, increasing unit shipments in sachet forms across multiple markets. These quantifiable new product events contribute to measurable expansion in form variety, flavor variants and dosage types captured in Antacids Market Research Report, Antacids Industry Report, Antacids Market Insights.

Five Recent Developments

• March 2024: Procter & Gamble acquired Rolaids brand transferring 1000 mg calcium carbonate / 200 mg magnesium hydroxide tablet formulations; the transaction added a top‑2 brand by unit share.
• June 2024: Akums Drugs (India) launched dual‑action chewable sodium alginate + potassium bicarbonate tablet approved by DCGI, one product innovation representing new segment entry.
• 2022: Sun Pharmaceuticals introduced Pepmelt mouth‑melting powder form dissolving instantly—entry into under‑10 % powder segment.
• 2023–2024: Haleon (TUMS) and Bayer (Alka‑Seltzer) expanded flavored chewable variants—several new flavors added (peppermint, tropical, fruit, etc.) quantifying SKU increases.
• 2024: Global online pharmacy channel share for antacids grew with implied 4.8 % CAGR in distribution share, reflecting quantitative shift in channel volumes.

Report Coverage of Antacids Market

The Antacids Market Report scope includes global and regional breakdowns extending across North America (44 % share in 2022), Europe (20–21 % share), Asia‑Pacific (>35 %), and Middle East & Africa (<10 %, fastest‑growing). It covers segmentation by type: tablets (25‑26 % share in 2024), liquids/suspensions (35 %), powders (<10 %), enabled by numerical formulation share data. End‑use coverage includes retail pharmacy (≈41.5 % share in 2022), hospital pharmacy, and online pharmacy channels (online showing 4.8 % CAGR in share), with quantified distribution split. It provides analysis of active ingredients: calcium carbonate (38.5 % share in 2024) and combined aluminium‑magnesium alkali (60 %+ share in 2023) data from industry sources.

Competitive landscape profiling includes Sanofi and Bayer AG among top two globally with double‑digit percent unit share each, followed by GSK, Pfizer, Takeda, Dr. Reddy’s, Reckitt, Sun Pharma in descending unit count order. Coverage also includes strategic developments: acquisitions (P&G‑Rolaids march 2024), product launches (Akums June 2024, Pepmelt 2022), flavor innovation counts across brands, regional product rollouts across Asia‑Pacific, Europe, North America, and channel investment trends in online distribution. Forecast period reflects measured projection in unit volume and regional volume distribution through 2030, including breakdown in dosage share and channel share.

Antacids Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 7396 Million in 2026
Market Size Value By	USD 9863.78 Million by 2035
Growth Rate	CAGR of 3.25% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Tablet Liquid Powder By Application : Retail Pharmacy Hospital Pharmacy Online Pharmacy
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample